Get started
INTELLIA THERAPEUTICS INCINTELLIA THERAPEUTICS INCINTELLIA THERAPEUTICS INC

INTELLIA THERAPEUTICS INC

No trades
See on Supercharts
Overview Financials News
Ideas
Minds Technicals Forecast

38I trade ideas

NTLA shortThis is only my second published idea and my last published trade was successful so with 100% accuracy the probability that this is going to pan out the way I want is infintesimal. Here goes anyways. This is at what I would consider a key level of resistance permitting for a tight stop loss but decent gains possible. If it goes towards my price target will I hang on until the price target? Not neccessarily, am doing speculation, constantly taking in new information.
NASDAQ:NTLAShort
by travis84
1
NTLA Intellia Therapeutics Inc. BPC Chart Overview 03/28/22Intellia Therapeutics Inc. NASDAQ: NTLA Chart Overview 03/28/22 Intellia is trading in a 9-month downward channel pullback, closing the gap created by the release of Phase 1 data of NTLA-2001 to treat ATTR. The release caused a bull pennant that led to a reversal into a downward channel. We are tracking support at $56 and a resistance line is at $90. The downward channel pullback may be forming a descending wedge, which could lead to a bullish breakout. Tracking RSI and MACD, the lowest lows on both charts are displaying a slight increase, running opposite to price, which lowest lows are continuing to decrease. The bullish divergence also indicates a possible breakout if met with an increase in volume. Good news could mean that the recent bottom is in, possible clinical holds, or other issues could test 2021 lows around $44. We will be looking for a breakout over $90 into a new bullish pattern. Intellia will be commencing Part 2 of its NTLA-2001 and is set to read out from its Phase 1/2 NTLA-2002 hereditary angioedema (HAE) trial this year. A recent loss in a CRISPR patent ruling increases uncertainty in the stock. Catalysts can have a profound effect on stock price and incorporating BioPharmCatalyst into your due diligence can ensure that you are prepared. Track 1000+ catalysts and access over 800+ companies’ fundamentals, earnings and analyst ratings by becoming a BPC Premium Subscriber. Sign up for your FREE trial at www.biopharmcatalyst.com Get a daily breakdown of biotech investor news straight to your inbox with our pre and post market newsletters sign up here www.biopharmcatalyst.com
NASDAQ:NTLA
by BioPharmCatalyst
Intellia devolving. NTLAGoals 61, 53. Invalidation at 110. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NASDAQ:NTLAShort
by Rykin_Capital
NTLA : SWING TRADEIntellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon Summary : Intellia is a gene therapy specialist pioneering CRISPR-Cas9 technology. Its recently released data in ATTR Amyloidosis stunned analysts, showing mean reduction in TTR Serum levels of up to 96%. This was the first ever clinical proof of the safety and efficacy of an in-vivo CRISPR genome editing technology in a human trial, and sent Intellia's share price up by >100%. Intellia will release more data from the trial and initiate a single-dose expansion cohort before the end of the year. SOURCE : Edmund Ingham, Aug. 31, 2021, Seeking Alpha seekingalpha.com
NASDAQ:NTLA
by TradingMavericks
NLTA: Should be heading to retest recent high of $200Healthcare sector seems bullish overall. Lots of stocks within this sector have bullish bias as well. NTLA have a pretty well defined ABCDE Triangle pattern, and any time now is a good time to enter. Stop loss below the low of C i.e. around $140. Disclaimer: I'm not giving any trading and investing advice. I'm just sharing my chart observations. If you have any symbols that you'd like me to analyze, feel free to drop me a comment.
NASDAQ:NTLALong
by leslieyimsm
6
NTLA - Consolidation in tight range - (8/30/21)Chart has consolidated very nicely since the earnings gap up. Since the gap up we have had sellers in control for a period of time (indicated by AVWAP from PEG) but has flipped to buyers being in control since price is above the AVWAP. As indicated with the white arrow it appears that this could be the higher low and we could be seeing some movement from this name. We have held the 23EMA very well and it is now catching up which could mean that the time needed for this to settle is complete. ATR (red line above chart) has been declining which is great after a PEG. The RSI has also stayed above 50 during this consolidation which is a good sign. Overall we have many factors working for us in this chart. I believe the best action on this would be to buy on a reversal day since those have been the best days to buy in this market. Any buys on the 23EMA is solid. Can use the 23EMA to manage risk or the AVWAP. On the bear side we have the top rectangle being a resistance point and it has tested this area about 4 times. Also you could say that the buyers and the sellers are still fighting for control since price has moved up and down the AVWAP but since the trend is your friend I will say this is a good sign. I think it is constructive because I think this is tiring out the sellers.
NASDAQ:NTLALong
by huntersanna33
Trade Setup: Buy/Long Intellia TherapeuticsKeeping an eye on this name for tomorrow's session. NTLA has been in a low volume consolidation since 'gaping' higher on the back of it's earnings. I'm not too concerned that I missed the reaction to earnings as my only goal is to be on the right side of the next 15 to 25%, whether that be long or short. In any case, I'm not always in favour of going into earnings (as new trade) with stock as anything is possible, especially in biotech. Provided we see a close above $164.90, or strong intraday price above this level, I believe it could be a swing long. Stop-loss: $151.90 Target: $193.00 Last Close: $162.33 NASDAQ:NTLA
NASDAQ:NTLALong
by LD_Perspectives
NTLA - PEG w/ Optimal R/R (8/23/2021)Price held at the 23EMA with a overall mixed week. Looking at the volume profile we are in between two strong nodes that have been controlling the trend. Price is below AVWAP but is moving sideways and not lower. Also have a declining 5EMA while lower term MA chop sideways as buyers and seller decide who is going to take control. Looking at the 30M timeframe seller still seem to be present but the buyers still remain in control of the overall trend. ATR and volume is declining which indicates a larger move is coming.
NASDAQ:NTLALong
by huntersanna33